GlassScriptPhysician profile
Michael D Peters
NPI 1194775429
$29,366.89
in general payments reported to CMS, 2019-2025
16 companies · $333 in 2025
The $333 reported for 2025 was more than what a typical Otolaryngology/Facial Plastic Surgery provider received nationally (typical 2025 total: $305).
See the full distribution for Otolaryngology/Facial Plastic Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $76.55 · 2021: $28K · 2022: $14.04 · 2023: $225 · 2024: $160 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $718.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $28,328.07 | 2020-2021 | |
| Genzyme Corporation | $276.20 | 2021-2025 | |
| Aerin Medical INC. | $187.30 | 2019-2025 | |
| Integra Lifesciences Corporation | $161.44 | 2025 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Acclarent, INC | $142.16 | 2019 | |
| Medtronic USA, INC. | $61.56 | 2019-2020 | |
| Oticon Medical, LLC | $43.39 | 2024 | Ponto Bone Anchored Hearing System |
| Glaxosmithkline, LLC. | $36.13 | 2023-2025 | Nucala |
| Galderma Laboratories, L.P. | $28.79 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $18.49 | 2025 | Tezspire |
| Idorsia Pharmaceuticals US INC | $16.12 | 2023 | Quviviq |
| Neurent Medical Limited | $14.83 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Abbott Laboratories | $14.04 | 2022 | |
| Optinose US, INC. | $13.17 | 2023 | |
| Smith+Nephew, INC. | $12.88 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $12.32 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Peters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.